Major GI Bleed on a Direct Oral Anticoagulant at a Hospital Without Andexanet
A 74-year-old woman presents with 6 hours of melena and one episode of coffee-ground emesis. She takes apixaban 5 mg twice daily for atrial fibrillation, last dose 10 hours ago, plus metoprolol and atorvastatin; she is not on a proton pump inhibitor. Vitals: HR 104 supine and 128 standing, BP 106/64 supine, RR 20, T 36.7 C, SpO2 97%. She is pale, diaphoretic, with epigastric tenderness but no rebound or guarding. Hemoglobin 7.4 g/dL (baseline 11.8 three months ago), platelets 180,000, INR 1.5, creatinine 1.6 mg/dL, eGFR 30 mL/min/1.73 m2. She weighs 58 kg. The formulary stocks 4-factor prothrombin complex concentrate but not andexanet alfa; transferring her to a center with andexanet would take about 3 hours. She is alert and asking whether she should stop her "blood thinner forever."
1. Stratify her bleeding risk, decide on reversal, and justify your choice given the drug availability constraint.
Read the worked answer
Risk: she has a major GI bleed - hemodynamically significant (standing tachycardia, narrow pulse pressure), symptomatic anemia, and a Glasgow-Blatchford score well into the high-risk range (BUN elevated, Hb <10, systolic BP ~100, HR ≥100, melena). She needs resuscitation, a type and screen with crossmatch, IV access x2, PPI infusion, and GI consultation for endoscopy.
Reversal reasoning:
- INR does not measure apixaban effect; do not use it to decide. An anti-Xa apixaban-calibrated assay, if rapidly available, is the useful test.
- Guidelines support specific reversal (andexanet alfa) or, where unavailable, 4-factor PCC for life-threatening bleeding - intracranial hemorrhage, hemodynamic instability, or bleeding into a closed space. Apixaban has a short half-life and the last dose was 10 hours ago (roughly 2 half-lives in a patient with reduced clearance), so some effect has already waned.
- A 3-hour transfer for andexanet in an actively bleeding patient is a real risk of decompensation; a reasonable judgment is to resuscitate aggressively, hold apixaban, activate the GI bleed pathway, and give 4F-PCC (about 50 units/kg, roughly 2900 units) if she remains unstable or deteriorates.
- If she stabilizes with crystalloid and blood products before PCC is given, supportive care with urgent endoscopy may be sufficient; PCC carries thrombotic risk and its evidence in DOAC-related GI bleeding is low quality. State your threshold in the note and reassess frequently.
Transfusion: restrictive strategy, target Hb about 7–8 g/dL, with faster thresholds if she remains tachycardic or shows ongoing bleeding.
2. After hemostasis is achieved at endoscopy, address her question about stopping the anticoagulant "forever" and plan restart timing.
Read the worked answer
First, validate the fear and reframe the trade-off. She has two competing risks: a gastrointestinal bleed if she restarts, and a stroke if she does not. Estimate them explicitly for her: with atrial fibrillation and a CHA2DS2-VASc score around 4–5 (age 74, female, plus her other risk factors), her annual stroke risk untreated is substantial - several percent per year, and strokes are frequently more disabling than a treated GI bleed.
Practical plan:
- Keep apixaban held through the acute bleed and early post-hemostasis period. Typical practice is to resume within roughly 4–7 days once hemostasis is confirmed and she is eating, in consultation with cardiology and gastroenterology. Earlier resumption favors stroke prevention; later favors rebleeding.
- Do not stop it permanently based on one bleed. Instead, modify risk: start a PPI (she was on none - this is a modifiable contributor), avoid NSAIDs and aspirin unless indicated, treat H. pylori if positive, and review other bleeding risks such as alcohol use and falls.
- Verify her dose is appropriate. Apixaban dose reduction requires two of three criteria: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL. She meets two (58 kg and creatinine 1.6), so the prescribing record and her prior dosing should be checked - if she has been on 5 mg twice daily, she may have been over-anticoagulated for her age and renal function. Confirm the intended dose with the prescriber rather than changing it unilaterally.
- Document a clear shared decision: restart date, who will follow up, and what to do if bleeding recurs. Give written instructions and a GI follow-up appointment before discharge.